Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 17/20 | 0.47 |
| ▸ | ERBB2 | P04626 | 7/20 | 0.47 |
| ▸ | NQO2 | P16083 | 1/20 | 0.47 |
| ▸ | FECH | P22830 | 1/20 | 0.47 |
| ▸ | MYH14 | Q7Z406 | 1/20 | 0.47 |
| ▸ | RIPK3 | Q9Y572 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | FBP1 | P09467 | 1/20 | 0.37 |
| ▸ | FLT1 | P17948 | 1/20 | 0.37 |
| ▸ | FLT4 | P35916 | 1/20 | 0.37 |
| ▸ | KDR | P35968 | 1/20 | 0.37 |
| ▸ | ERBB4 | Q15303 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24569409 | 1.00 | EGFR (0.47) | EGFRERBB2NQO2FECHMYH14 | |
| SCHEMBL29888075 | 1.00 | EGFR (0.47) | EGFRERBB2NQO2FECHMYH14 | |
| SCHEMBL24569870 | 0.91 | HTT (0.55) | EGFRERBB2NQO2FECHMYH14 | |
| SCHEMBL29888850 | 0.90 | EGFR (0.49) | EGFRERBB2NQO2FECHMYH14 | |
| SCHEMBL24569385 | 0.90 | EGFR (0.49) | EGFRERBB2NQO2FECHMYH14 | |
| SCHEMBL24167890 | 0.90 | EGFR (0.48) | EGFRERBB2NQO2FECHMYH14 | |
| SCHEMBL24167630 | 0.85 | MAPT (0.51) | EGFRERBB2NQO2FECHMYH14 | |
| SCHEMBL26008684 | 0.85 | EGFR (0.44) | EGFRERBB2NQO2FECHMYH14 | |
| SCHEMBL25432434 | 0.85 | EGFR (0.45) | EGFRERBB2NQO2FECHMYH14 | |
| SCHEMBL25432467 | 0.85 | EGFR (0.45) | EGFRERBB2NQO2FECHMYH14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4476211-A1 | ACYLATED HETEROCYCLIC QUINAZOLINE DERIVATIVES AS INHIBITORS OF ERBB2 | Enliven Inc. (US) | 2024-12-18 | — | — | EP | disclosed |
| EP-4267137-A1 | LACTAM (HETERO)ARYLFUSEDPYRIMIDINE DERIVATIVES AS INHIBITORS OF ERBB2 | Enliven Inc. (US) | 2023-11-01 | — | — | EP | disclosed |
| WO-2023154124-A1 | ACYLATED HETEROCYCLIC QUINAZOLINE DERIVATIVES AS INHIBITORS OF ERBB2 | ENLIVEN THERAPEUTICS, INC. (US) | 2023-08-17 | — | — | WO | disclosed |
| WO-2022140769-A1 | LACTAM (HETERO)ARYLFUSEDPYRIMIDINE DERIVATIVES AS INHIBITORS OF ERBB2 | ENLIVEN THERAPEUTICS, INC. (US) | 2022-06-30 | — | — | WO | disclosed |